IL受容体
- 阻害剤の選択性比較
- 溶解度
| カタログ番号 | 製品カタログ | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | アルコール | ||
| S4028 | Dexamethasone Sodium Phosphate | 103 mg/mL | <1 mg/mL | <1 mg/mL |
| S2015 | Suplatast Tosylate | 100 mg/mL | 100 mg/mL | 100 mg/mL |
| S4267 | Diacerein | <1 mg/mL | 48 mg/mL | <1 mg/mL |
| S8696 | 2-D08 | <1 mg/mL | 54 mg/mL | <1 mg/mL |
| S8663 | Takinib | <1 mg/mL | 64 mg/mL | <1 mg/mL |
| S8562 | CA-4948 | <1 mg/mL | 30 mg/mL | <1 mg/mL |
| S4028 | Dexamethasone Sodium Phosphate | 103 mg/mL | <1 mg/mL | <1 mg/mL |
| S2015 | Suplatast Tosylate | 100 mg/mL | 100 mg/mL | 100 mg/mL |
| S4267 | Diacerein | <1 mg/mL | 48 mg/mL | <1 mg/mL |
| S8696 | 2-D08 | <1 mg/mL | 54 mg/mL | <1 mg/mL |
| S8663 | Takinib | <1 mg/mL | 64 mg/mL | <1 mg/mL |
| S8562 | CA-4948 | <1 mg/mL | 30 mg/mL | <1 mg/mL |
- IL Receptor阻害剤(16)
- 新IL Receptor製品
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| A2011新 |
SarilumabSarilumab is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD. |
||
| A2012新 |
TocilizumabTocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD. |
||
| S4028 |
Dexamethasone Sodium PhosphateDexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. |
Dexamethasone and largazole cooperate to suppress invasion and to restore E-cadherin localization to the cell peripher y. ( a) Phase contrast micrographs showing morphological changes in MDA-MB-231 cells induced by E-cadherin expression combined with 100 nM dexamethasone and 10 nM largazole treatments. Insets show the cells at higher magnification. (b ) Fluorescence (E-Cad-GFP) or immunofluorescence microscopy (g -catenin (g-Cat.)) of 231/E-Cad-GFP cells treated for 72 h with vehicle (Control), 100 n M dexamethasone, 10 nM largazole or 100 nM dexamethasone + 10 nM largazole (Dex. + Larg.). (c ) Invasion assays were per formed with the indicated cell lines treated for 72 h with or without 100 nM dexamethasone + 10 nM largazole using modified Boyden chambers impregnated with matrigel. The results are presented as the average number of cells that invaded through the membrane per field s.d. of five randomly chosen fields, and are representative of three independently per formed experiments. |
|
| S2015 |
Suplatast TosylateSuplatast Tosilate is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM. |
||
| S4267 |
DiacereinDiacerein is an inhibitor of pro-inflammatory cytokine Interleukin-1B (IL-1B) production, prescribed for osteoarthritis and chronic inflammatory arthritis. |
f, Intra-TG injection of IL-1β inhibitor, Diacerein 10 days after pIONL alleviated pIONL-induced mechanical allodynia from 1 to 6 h. *P < 0.05, ***P < 0.001. Two-way repeated measures ANOVA followed by Bonferroni test. |
|
| S8696新 |
2-D082-D08 is a cell permeable, mechanistically unique inhibitor of protein sumoylation. It is also inhibits Axl, IRAK4, ROS1, MLK4, GSK3β, RET, KDR and PI3Kα with IC50 values of 0.49, 3.9, 5.3, 9.8, 11, 11, 17 and 35 nM respectively in biochemical assays. |
||
| S8663新 |
TakinibTakinib is a potent and selective TAK1 inhibitor with an IC50 of 9.5 nM, more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. |
||
| S8562新 |
CA-4948CA-4948 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades, and demonstrates pharmacodynamic and antitumor activity in in vitro and in vivo nonclinical models. |
||
| A2011新 |
SarilumabSarilumab is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD. |
||
| A2012新 |
TocilizumabTocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD. |
||
| S4028 |
Dexamethasone Sodium PhosphateDexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. |
Dexamethasone and largazole cooperate to suppress invasion and to restore E-cadherin localization to the cell peripher y. ( a) Phase contrast micrographs showing morphological changes in MDA-MB-231 cells induced by E-cadherin expression combined with 100 nM dexamethasone and 10 nM largazole treatments. Insets show the cells at higher magnification. (b ) Fluorescence (E-Cad-GFP) or immunofluorescence microscopy (g -catenin (g-Cat.)) of 231/E-Cad-GFP cells treated for 72 h with vehicle (Control), 100 n M dexamethasone, 10 nM largazole or 100 nM dexamethasone + 10 nM largazole (Dex. + Larg.). (c ) Invasion assays were per formed with the indicated cell lines treated for 72 h with or without 100 nM dexamethasone + 10 nM largazole using modified Boyden chambers impregnated with matrigel. The results are presented as the average number of cells that invaded through the membrane per field s.d. of five randomly chosen fields, and are representative of three independently per formed experiments. |
|
| S2015 |
Suplatast TosylateSuplatast Tosilate is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM. |
||
| S4267 |
DiacereinDiacerein is an inhibitor of pro-inflammatory cytokine Interleukin-1B (IL-1B) production, prescribed for osteoarthritis and chronic inflammatory arthritis. |
f, Intra-TG injection of IL-1β inhibitor, Diacerein 10 days after pIONL alleviated pIONL-induced mechanical allodynia from 1 to 6 h. *P < 0.05, ***P < 0.001. Two-way repeated measures ANOVA followed by Bonferroni test. |
|
| S8696新 |
2-D082-D08 is a cell permeable, mechanistically unique inhibitor of protein sumoylation. It is also inhibits Axl, IRAK4, ROS1, MLK4, GSK3β, RET, KDR and PI3Kα with IC50 values of 0.49, 3.9, 5.3, 9.8, 11, 11, 17 and 35 nM respectively in biochemical assays. |
||
| S8663新 |
TakinibTakinib is a potent and selective TAK1 inhibitor with an IC50 of 9.5 nM, more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. |
||
| S8562新 |
CA-4948CA-4948 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades, and demonstrates pharmacodynamic and antitumor activity in in vitro and in vivo nonclinical models. |
